Chicago, IL – April 30, 2025:Presenters of two abstracts with preclinical data on ERX-208 and ERX-315 have won awards at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.Adriana Baker, who presented…
https://etira.life/wp-content/uploads/2025/04/AACR-2025-graphic-2K-e1746033763417.jpg10171083Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2025-04-30 11:25:242025-04-30 12:09:39Research on Etira drugs win awards at AACR 2025
Chicago, IL - April 23, 2025:
Three abstracts with preclinical data on ERX-208 and ERX-315 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 in San Diego. These abstracts will establish ERX-208 as…
https://etira.life/wp-content/uploads/2025/04/Unknown.png14001266Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2025-04-24 14:25:482025-04-29 11:04:51Preclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
Adelaide, Australia – March 17, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, has now activated a second site for recruitment of patients for the ERX-315-001 clinical trial at Cancer Research…
https://etira.life/wp-content/uploads/2025/03/image.png6821096Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2025-03-17 11:03:202025-03-17 11:03:20Second site activated for ERX-315 trial
Sydney, Australia – February 20, 2025: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced today that a patient has been successfully dosed at Dose Level Three (DL3) of ERX-315 in its Phase…
Dallas, TX - December 2, 2024: Etira, a clinical-stage biotechnology company pioneering novel approaches to treating cancer by inducing endoplasmic reticulum stress, today announced the appointment of Etira Co-Founder, Ganesh Raj, M.D., Ph.D.,…
https://etira.life/wp-content/uploads/2024/12/image.png566658Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-12-02 10:06:322024-12-03 11:33:29Dr. Raj appointed as Etira Chief Medical Officer
Sydney, Australia - November 18, 2024: We are excited to announce that the first patient in our ERX-315-101 Phase 1 clinical trial has successfully received their first doses of ERX-315 at The Kinghorn Cancer Center (TKCC) in Sydney, Australia.…
Dallas, TX – October 8, 2024: Etira, a clinical-stage biopharmaceutical company developing breakthrough cancer therapies, announced the appointment of Annalisa Jenkins, MBBS, FRCP and Justin Stebbing, BM, BCh, MA (oxon), FRCP FRCPath,…
Seattle, WA - September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th…
https://etira.life/wp-content/uploads/2024/09/Unknown.jpeg8191276Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-09-23 10:22:362024-09-24 11:49:29Validation of ERX-208 in Ovarian Cancer
Sydney, Australia – September 4, 2024: The Etira team, led by Founder Dr. Ganesh Raj, and the clinical Contract Research Organization Novotech successfully performed the site initiation visit at the Kinghorn Cancer Center (TKCC) in Sydney…
https://etira.life/wp-content/uploads/2024/09/image.png15682324Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-09-04 10:06:482024-10-15 12:30:25ERX-315-001 SITE INITIATION VISIT @TKCC
Dallas, TX – August 1, 2024: Etira is pleased to announce the approval of the ERX-315 Phase 1 clinical trial by the Australian Human Research Ethics Committee (HREC). This HREC approval enables the start of the clinical trial titled "A Phase…
https://etira.life/wp-content/uploads/2024/08/shutterstock_700277188_edited.jpeg690812Ilona Margolishttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngIlona Margolis2024-08-01 11:49:472024-10-15 12:30:01ERX-315 CLINICAL TRIAL APPROVED BY HREC
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
Research on Etira drugs win awards at AACR 2025
NewsPreclinical data on ERX-208 and ERX-315 to be presented at AACR 2025
NewsSecond site activated for ERX-315 trial
NewsERX-315 Phase 1 Clinical Trial Update
NewsDr. Raj appointed as Etira Chief Medical Officer
NewsFirst patient dosed in ERX-315-101 Clinical Trial
NewsDrs. Jenkins and Stebbing join Etira Board
NewsValidation of ERX-208 in Ovarian Cancer
NewsERX-315-001 SITE INITIATION VISIT @TKCC
NewsERX-315 CLINICAL TRIAL APPROVED BY HREC
News